NASDAQ$IDYA
IDEAYA Biosciences Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Announced financial results for the third quarter ended September 30, 2023 and provided a business update.
IDEAYA Biosciences reported a strong balance sheet with $511.1 million in cash, cash equivalents, and marketable securities as of September 30, 2023, supplemented by $134.7 million in estimated net proceeds from a subsequent follow-on financing and $10.0 million receivable from GSK milestones. The company is advancing its clinical pipeline with multiple ongoing trials for darovasertib, IDE397, and IDE161, and has achieved IND clearance for GSK101, triggering a $7.0 million milestone payment from GSK.
- Strong balance sheet with $511.1 million in cash, cash equivalents, and marketable securities as of September 30, 2023, supplemented by $134.7 million from follow-on financing and $10.0 million receivable from GSK milestones.
- Multiple patients dosed in Phase 2/3 trial evaluating darovasertib and crizotinib combination in 1L HLA-A2-negative MUM, with oral presentation at ESMO 2023.
- Enrollment ongoing in Phase 1/2 study with IDE397 (MAT2A) and AMG 193 (PRMT5MTA) in MTAP-deletion solid tumors.
- IND clearance for GSK101 (IDE705) Pol Theta Helicase inhibitor ($7.0 million milestone), and selected Werner Helicase Inhibitor Development Candidate ($3.0 million milestone).
Headline financials
Revenue & EPS history
IDEAYA · Revenue · Quarterly
$8.04M
Revenue by segment
IDEAYA · $8.04M total across 1 segment · Q3 2023
- Collaboration Revenue$8.04M—100.0%
Forward guidance
IDEAYA is targeting multiple wholly-owned next-generation development candidate nominations in 2024 and clinical program updates in the fourth quarter of 2023.
Tailwinds
- Targeting multiple wholly-owned next generation development candidate nominations in 2024, including in MTAP-deletion, further advancing IDEAYA’s multi-pronged strategy
- Targeting first-in-human studies for GSK101 in the fourth quarter of 2023
- Targeting IDE161 clinical program updates in the fourth quarter of 2023
- IND submission is targeted in 2024 to enable clinical evaluation of the Werner Helicase Inhibitor DC in patients having tumors that are microsatellite instability, or MSI, high.
- IDEAYA Investor R&D Day will include participation from GSK and a key opinion leader
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+1.4%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+6.7%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+40.5%
Q3 2019
Best reaction
-31.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.9% | +1.2% | |
| Q4 2025 | +1.6% | +5.6% | +7.7% | |
| Q3 2025 | -2.7% | -3.6% | +14.8% | |
| Q1 2025 | +2.9% | +10.6% | +28.1% | |
| Q4 2024 | -5.4% | -6.9% | -15.4% | |
| Q3 2024 | +3.4% | +9.4% | -0.9% | |
| Q2 2024 | -3.1% | +2.4% | +1.0% | |
| Q1 2024 | -3.9% | -4.5% | -8.0% | |
| Q4 2023 | -6.0% | -2.7% | -3.2% | |
| Q3 2023 | +6.9% | +1.6% | +8.1% | |
| Q2 2023 | +1.2% | +3.3% | +12.9% | |
| Q1 2023 | +15.6% | +10.2% | +31.5% | |
| Q4 2022 | +2.1% | -8.7% | -16.0% | |
| Q3 2022 | -3.4% | -1.8% | -2.5% | |
| Q2 2022 | -31.4% | -34.8% | -20.1% | |
| Q1 2022 | +13.0% | +26.4% | +48.4% | |
| Q4 2021 | -2.2% | +3.8% | -11.1% | |
| Q3 2021 | +3.9% | +0.8% | -4.1% | |
| Q2 2021 | -3.5% | +1.0% | +14.1% | |
| Q1 2021 | +7.8% | +1.7% | +12.5% | |
| Q4 2020 | -8.2% | -2.8% | -15.9% | |
| Q3 2020 | +2.5% | +6.3% | +9.3% | |
| Q2 2020 | -1.2% | -1.7% | +4.8% | |
| Q1 2020 | -9.4% | -0.6% | -5.3% | |
| Q4 2019 | +13.6% | +14.9% | +40.8% | |
| Q3 2019 | +40.5% | +30.6% | +29.6% | |
| Q2 2019 | +6.0% | -1.5% | +19.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro